Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Co-occurring psychiatric disorders are key determinants of disability in alcohol use disorder: a cross-sectional analysis in 157 recently detoxified patients.

Alcohol and alcoholism (Oxford, Oxfordshire)·2026
Same author

Prevalence and Factors Associated with Sexual Addiction in Men Who Have Sex with Men Seeking Treatment for Problematic Chemsex: Findings from the CHAMELEON Cross-Sectional Study.

Archives of sexual behavior·2026
Same author

Fast Muscle-parameter Calibration using EMG and Markerless Kinematics for Neuromusculoskeletal Modeling: Application to Hand-cycling.

IEEE transactions on bio-medical engineering·2026
Same author

Multibipolar radiofrequency <i>vs</i> single needle microwave ablation for the treatment of newly diagnosed hepatocellular carcinoma.

World journal of gastroenterology·2026
Same author

Restoring hand grasping for patients with a complete tetraplegia with selective epineural stimulation: a parsimonious thus relevant clinical approach.

Journal of neuroengineering and rehabilitation·2026
Same author

Cabozantinib for Hepatocellular Carcinoma in Real-World Practice (CLERANCE): A Prospective, Interventional Study.

Liver cancer·2025

Related Experiment Video

Updated: Jun 14, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Management of nonresponsive hepatitis C.

François Bailly1, Si Nafa Si Ahmed, Pierre Pradat

  • 1INSERM, U871, Lyon, France.

Expert Review of Anti-Infective Therapy
|April 10, 2010
PubMed
Summary

Many hepatitis C virus (HCV) patients don't respond to standard therapy but retreatment can be beneficial. Optimized regimens and new anti-HCV drugs offer improved outcomes for non-responders.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Over 50% of hepatitis C virus (HCV)-infected patients exhibit non-response to standard pegylated interferon (PEG-IFN)/ribavirin therapy.
  • Treatment failure after initial therapy does not preclude successful outcomes with subsequent retreatment strategies.

Purpose of the Study:

  • To explore alternative retreatment strategies for HCV patients who did not respond to initial therapy.
  • To discuss the potential benefits of optimized drug regimens, comorbidity management, and novel anti-HCV agents.

Main Methods:

  • Review of existing literature on HCV retreatment strategies.
  • Analysis of optimized standard-of-care regimens including ribavirin concentration adjustment and comorbidity correction.
  • Consideration of novel anti-HCV molecules and interferon-based options.

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Related Experiment Videos

Last Updated: Jun 14, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Main Results:

  • Retreatment, particularly with optimized regimens and new agents, can be beneficial for non-responders.
  • Maintenance therapy may slow complications in advanced HCV disease, though requires further clinical validation.
  • Noninvasive fibrosis assessment and genetic testing are emerging tools for predicting treatment response.

Conclusions:

  • HCV retreatment offers a viable path for non-responders, utilizing optimized standard care and new antiviral therapies.
  • Personalized approaches, including maintenance therapy and predictive diagnostics, are crucial for managing advanced HCV.
  • Further clinical trials are needed to validate novel maintenance strategies and fully leverage emerging diagnostic tools.